177 related articles for article (PubMed ID: 17629370)
1. Role of interferon-gamma during CpG oligodeoxynucleotide-adjuvanted immunization with recombinant proteins.
Rosa DS; Bastos KR; Bargieri DY; Tzelepis F; Nomizo A; Russo M; Soares IS; Rodrigues MM
Vaccine; 2007 Aug; 25(32):6007-17. PubMed ID: 17629370
[TBL] [Abstract][Full Text] [Related]
2. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
3. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
Nyström-Asklin J; Adamsson J; Harandi AM
Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells stimulated with cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively reduce outgrowth of established tumors in vivo.
Hiraide A; Hiroishi K; Eguchi J; Ishii S; Doi H; Imawari M
Cancer Sci; 2008 Aug; 99(8):1663-9. PubMed ID: 18754881
[TBL] [Abstract][Full Text] [Related]
5. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex.
Jones DE; Palmer JM; Burt AD; Walker C; Robe AJ; Kirby JA
Hepatology; 2002 Sep; 36(3):679-86. PubMed ID: 12198661
[TBL] [Abstract][Full Text] [Related]
6. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
7. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
[TBL] [Abstract][Full Text] [Related]
8. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
10. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
[TBL] [Abstract][Full Text] [Related]
11. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides.
Zelenay S; Elías F; Fló J
Eur J Immunol; 2003 May; 33(5):1382-92. PubMed ID: 12731065
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
13. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii.
Saavedra R; Leyva R; Tenorio EP; Haces ML; Rodríguez-Sosa M; Terrazas LI; Hérion P
Parasite Immunol; 2004 Feb; 26(2):67-73. PubMed ID: 15225293
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation.
Kuwajima S; Sato T; Ishida K; Tada H; Tezuka H; Ohteki T
Nat Immunol; 2006 Jul; 7(7):740-6. PubMed ID: 16715101
[TBL] [Abstract][Full Text] [Related]
15. Antimetastatic effect of CpG DNA mediated by type I IFN.
Hafner M; Zawatzky R; Hirtreiter C; Buurman WA; Echtenacher B; Hehlgans T; Männel DN
Cancer Res; 2001 Jul; 61(14):5523-8. PubMed ID: 11454702
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase.
Wang S; Han Q; Zhang G; Zhang N; Li Z; Chen J; Lv Y; Li N; Xing F; Tian N; Zhu Q; Liu Z
Int Immunopharmacol; 2011 Apr; 11(4):406-11. PubMed ID: 21182997
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to swine streptococcic septicemia vaccine in weaned piglets.
Linghua Z; Xingshan T; Fengzhen Z
Mol Immunol; 2007 Feb; 44(6):1141-9. PubMed ID: 16911828
[TBL] [Abstract][Full Text] [Related]
19. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
20. CpG ODN enhances immunization effects of hepatitis B vaccine in aged mice.
Qin W; Jiang J; Chen Q; Yang N; Wang Y; Wei X; Ou R
Cell Mol Immunol; 2004 Apr; 1(2):148-52. PubMed ID: 16212903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
